ClinicalTrials.gg
Status unknownNCT02523547Updated Aug 14, 2015

Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude

A Phase 4 interventional study of Cavir and Baraclude in Chronic Hepatitis B, sponsored by Hanmi Pharmaceutical Company Limited. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2015-08-14.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2015), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Planned enrollment
25th of 61
134 · median 109
Started
2015
with 4 others
Phase 4
33 of 64
2 open now
Registered
49th of 64
by date

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 25th largest by planned enrollment of the 61 interventional ones that give a count, is one of 5 that started in 2015, is one of 33 in phase 4, and was the 49th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

Open-labeled, Prospective, Randomized, Multi-center, Interventional, Phase IV study.

Read the detailed description

The purpose of this study is to evaluate the non-inferiority and safety in terms of HBV DNA undetectability comparing Baraclude Tab. in HBeAg(+) chronic hepatitis B patients treated with long-term Baraclude Tab.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

Keywords

  • entecavir
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients (over the19 years of age) currently taking Baraclude® monotherapy for chronic infection for at least 24 month with \< HBV DNA 60 IU/mL level, HBeAg positive and HBeAb negative status at screening.

Exclusion criteria

Exclusion Criteria:

  • Patients are diagnosed Hepatitis cancer and hepatocellular carcinoma (HCC)
  • Patient has concomitant other chronic viral infection (HAV/ Virus (HCV)/Hepatitis D Virus(HDV)/)
  • Patient had documented resistance mutations at any time before or at screening
  • Patient has clinically confirmed alcoholism, hepatitis, with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency and Wilson's Disease.
  • Patient has received antiviral agent including interferon other than Baraclude within 24 months before screening for this study.
  • Patient has received agent within 24 weeks before screening or for 4 weeks.
  • Clinical signs as indicated by any one of the following: Ccr(Cockroft-Gault) \< 50ml/min, Total > 3.0 mg/dl, Albumin \< 2.7 g/dl, > INR 2.3
  • Patient is pregnant or breastfeeding or willing to be pregnant
  • Patient has malignancy except for thyroid cancer and Borderline malignancy.a history of treated malignancy is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding five years
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Cavir

    entecavir/0.5mg/day

    Drug: Cavir

  • Active comparator
    Baraclude

    entecavir/0.5mg/day

    Drug: Baraclude

Interventions

  • DrugCavir

    0.5mg/day

    Also known as: entecavir

  • 0.5mg/day

    Also known as: entecavir

06

What researchers measure

Primary outcomes

  1. The proportion of patients with maintenance of HBV DNA undetectability

    analysis

    Time frame: 48weeks

Secondary outcomes

  1. The proportion of patients with HBeAg seroconversion

    analysis

    Time frame: at week 12, 24, 36 and 48 of treatment

  2. The proportion of patients with HBeAg seroclearance

    analysis

    Time frame: at week 12, 24, 36 and 48 of treatment

  3. The proportion with HBsAg seroclearance

    analysis

    Time frame: at week 48 of treatment

  4. The proportion with HBeAg seroconversion and HBsAb positive

    analysis

    Time frame: at week 48 of treatment

  5. Changes in serum HBV DNA levels

    analysis

    Time frame: at week 48 of treatment

  6. Changes in HBsAg titer

    analysis

    Time frame: at week 48 of treatment

  7. Changes in ALanine amino Transferase (ALT)

    analysis

    Time frame: at week 48 of treatment

  8. Proportion of patients with virologic breakthrough

    virologic breakthrough is defined as the increase in serum HBV DNA (\>60IU/ml) as determined by at least 2 consecutive measurements of at least 3 month apart, during continued treatment

    Time frame: at week 48 of treatment

  9. Changes in EuroQoL Five Dimensions Questionnaire-3L(EQ-5D-3L)

    questionnaire

    Time frame: at week 48 of treatment

07

Study locations

1 of 1 sites recruiting
  • 15 Sites
    Seoul, Korea, Republic of
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2015
First posted
Aug 14, 2015
Start
Jan 2015
Primary completionEst.
Feb 2017
CompletionEst.
Feb 2017
Last update
Aug 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02523547
Responsible party
Sponsor
First posted
Aug 14, 2015
Start date
Jan 2015
Primary completion
Feb 2017 (estimated)
Completion
Feb 2017 (estimated)
Last update
Aug 14, 2015

Study contacts

Hanmi Pharmaceutical
Contact
EunSol Kim
Contact
snow-white@hanmi.co.kr
+82-2-410-8747

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion